Collegium Pharmaceutical - COLL Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COLL shares.
View COLL analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12 month price targets for Collegium Pharmaceutical's shares. Their COLL share price forecasts range from $26.00 to $42.00. On average, they expect the company's stock price to reach $33.25 in the next year. This suggests a possible upside of 106.3% from the stock's current price.
View analysts price targets for COLL or view top-rated stocks among Wall Street analysts.

Collegium Pharmaceutical's stock was trading at $18.68 on January 1st, 2022. Since then, COLL shares have decreased by 13.7% and is now trading at $16.12.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our COLL earnings forecast.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its quarterly earnings results on Thursday, August, 4th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $1.15 by $1.19. The specialty pharmaceutical company earned $123.55 million during the quarter, compared to the consensus estimate of $122.63 million. Collegium Pharmaceutical had a negative net margin of 11.24% and a negative trailing twelve-month return on equity of 2.12%.

Collegium Pharmaceutical updated its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $450.00 million-$465.00 million, compared to the consensus revenue estimate of $455.26 million.

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of COLL stock can currently be purchased for approximately $16.12.

Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $550.18 million and generates $276.87 million in revenue each year. The specialty pharmaceutical company earns $71.52 million in net income (profit) each year or ($1.05) on an earnings per share basis.

The company employs 152 workers across the globe.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com.